NCT00257686

Brief Summary

The purpose of this study is to compare the efficacy and safety of pitavastatin with that of pravastatin in elderly patients

Trial Health

93
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
962

participants targeted

Target at P75+ for phase_3

Timeline
Completed

Started Sep 2005

Shorter than P25 for phase_3

Geographic Reach
5 countries

62 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2005

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

November 21, 2005

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 23, 2005

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2006

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2006

Completed
3.7 years until next milestone

Results Posted

Study results publicly available

January 18, 2010

Completed
Last Updated

March 16, 2010

Status Verified

March 1, 2010

Enrollment Period

8 months

First QC Date

November 21, 2005

Results QC Date

August 26, 2009

Last Update Submit

March 9, 2010

Conditions

Keywords

KowaHypercholesterolemiacombineddyslipidemiaelderlypitavastatinNK-104

Outcome Measures

Primary Outcomes (1)

  • Percent Change From Baseline in LDL-C

    Percent change from baseline in low density cholesterol (LDL-C)

    Baseline to 12 weeks

Secondary Outcomes (1)

  • Percent Change From Baseline in TC

    Baseline to 12 weeks

Study Arms (6)

Pitavastatin 1 mg

EXPERIMENTAL

Pitavastatin 1 mg once daily

Drug: Pitavastatin

Pravastatin 10 mg

ACTIVE COMPARATOR

Pravastatin 10 mg once daily

Drug: Pravastatin

Pitavastatin 2 mg

EXPERIMENTAL

Pitavastatin 2 mg once daily

Drug: Pitavastatin

Pravastatin 20 mg

ACTIVE COMPARATOR

Pravastatin 20 mg once daily

Drug: Pravastatin

Pitavastatin 4 mg

EXPERIMENTAL

Pitavastatin 4 mg once daily

Drug: Pitavastatin

Pravastatin 40 mg

ACTIVE COMPARATOR

Pravastatin 40 mg once daily

Drug: Pravastatin

Interventions

Pitavastatin 1 mgPitavastatin 2 mgPitavastatin 4 mg
Pravastatin 10 mgPravastatin 20 mgPravastatin 40 mg

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • Males and postmenopausal females (aged 65 years and older
  • Eligible, able to participate, have given informed consent
  • Must have been following a restrictive diet
  • Diagnosis of primary hypercholesterolemia or combined dyslipidemia
  • Serum CK must be less than or equal to 1.5 x ULRR at 2 of 3 permitted evaluations between Week -4 and -1
  • Agree to be available

You may not qualify if:

  • Homozygous familial hypercholesterolemia
  • Conditions which may cause secondary dyslipidemia
  • Uncontrolled diabetes mellitus (HbA1c \>8%).
  • Any condition which might significantly alter the absorption, distribution, metabolism, or excretion of any drug.
  • History of pancreatic injury or pancreatitis, or impaired pancreatic function/injury
  • Liver injury
  • Impaired renal function
  • Current obstruction of the urinary tract or difficulty in voiding due to mechanical as well as inflammatory conditions, which is likely to require intervention during the course of the study or is regarded as clinically meaningful
  • Serum CK \>5 x ULRR without clinical explanation
  • Uncontrolled hypothyroidism defined as TSH \>ULRR
  • Any severe acute illness or severe trauma in the last 3 months prior to Visit 1
  • Major surgery, 3 months prior to Visit 1
  • Significant CVD prior to randomization
  • Evidence of symptomatic heart failure, gross cardiac enlargement; significant heart block or cardiac arrhythmias. History of uncontrolled complex ventricular arrhythmias, uncontrolled atrial fibrillation/flutter or uncontrolled supraventricular tachycardias with a ventricular response rate of \> 100 beats per minute at rest.
  • Left ventricular ejection fraction \<0.25;
  • +14 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (62)

CCBR A/S

Aalborg, Denmark

Location

Copenhagen University Hospital

Copenhagen, Denmark

Location

Medical Center

Copenhagen, Denmark

Location

CCBR A/S

Vejle, Denmark

Location

Kardiologische Gemeinschaftspraxis Prof. Reifart

Bad Soden / Taunus, Germany

Location

Praxis Dr. Boenninghoff

Beckum, Germany

Location

Klinische Forschung Berlin Mitte

Berlin, Germany

Location

GWT-TUK mbH, Zentrum fur Klinische Studien

Dresden, Germany

Location

Gemeinschaftspraxis Dr. Krause, Th. Menke

Goch, Germany

Location

Klinische Forschung Hamburg

Hamburg, Germany

Location

Innere Medizin I / Medizinische Klinik

Heidelberg, Germany

Location

Gemeinschaftspraxis H. Holz Dr. med, K. W. Klingl

Lampertheim, Germany

Location

ZET-Studien GmbH Leipzing

Leipzig, Germany

Location

Internistische Gemeinschaftspraxis

Mainz, Germany

Location

Praxis Dr. Wachter

Mannheim, Germany

Location

Gemeinschaftspraxis Melcherstaette

Melcherstaette, Germany

Location

Gemeinschaftspraxis Dr. Senftleber, Dr. Kohler

Messkirch, Germany

Location

Praxisgemeinschaft im Kleinen Biergrund

Offenbach/M, Germany

Location

Gemeinschaftspraxis Melcherstaette

Stuhr-Brinkum, Germany

Location

Gemeinschaftspraxis Drs. Mockesch

Weinheim, Germany

Location

Intermed Institud Fur Klinische Forschung und Arzn

Wiesbaden, Germany

Location

Gemeinschaftspraxis Dr. Emden, Frank Drewes

Worpswede, Germany

Location

Department of Internal Medicine, Soroka Medical Center

Beersheva, Israel

Location

Department of Internal Medicine A, Rambal Medical Center

Haifa, Israel

Location

Department of Internal Medicine, Wolfson Medical Center

Holon, Israel

Location

Center for Research, Hadassah University Hospital

Jerusalem Ein Kerem, Israel

Location

Meir Hospital

Kfar Saba, Israel

Location

Department of Medicine, Hadassah Medical Center

Mount Scopus Jerusalem, Israel

Location

Department of Internal Medicine, Rivka Sieff Medical Center

Safed, Israel

Location

Institute of Metabolic Diseases

Tel Aviv, Israel

Location

Institue of Lipid & Atherosclerosis Research

Tel Litwinsky, Israel

Location

Andromed Oost

ES Velp, Netherlands

Location

Andromed Noord

Groningen, Netherlands

Location

Vasculair Onderzoek Centrum Hoorn

Hoorn, Netherlands

Location

Andromed Leiden

Leiden, Netherlands

Location

Andromed Nijmegen

Rotterdam, Netherlands

Location

Andromed Rotterdam

Rotterdam, Netherlands

Location

Albert Schweitzer ziekenhuis

Sliedrecht, Netherlands

Location

Andromed Breda

VL Breda, Netherlands

Location

Rivierenland Tiel

WP Tiel, Netherlands

Location

Andromed Zoetermeer

Zoetermeer, Netherlands

Location

Albert Schweitzer ziekenhuis

Zwijndrecht, Netherlands

Location

Oldfield Surgery

Bath, United Kingdom

Location

St James's Surgery

Bath, United Kingdom

Location

The Pulteney Practice

Bath, United Kingdom

Location

Birmingham Clinical Research Centre

Birmingham, United Kingdom

Location

Stonehill Medical Center

Bolton, United Kingdom

Location

Chorley Clinical Research Centre

Chorley, United Kingdom

Location

Saltash Health Center

Cornwall, United Kingdom

Location

Gomersal Lane Surgery

Dronfield, United Kingdom

Location

Townhead Research

Irvine, United Kingdom

Location

Crosby Clinical Research Centre

Liverpool, United Kingdom

Location

The Symons Medical Center

Maidenhead, United Kingdom

Location

Manchester Clinical Research Centre

Manchester, United Kingdom

Location

Greenwood Medical Center

Nottingham, United Kingdom

Location

Reading Clinical Research Centre

Reading, United Kingdom

Location

Elm Lane Surgery

Sheffield, United Kingdom

Location

Brook Lane Surgery

Southampton, United Kingdom

Location

Bradford Road Medical Center

Wiltshire, United Kingdom

Location

Rowden Medical Partnership

Wiltshire, United Kingdom

Location

The Porch Surgery

Wiltshire, United Kingdom

Location

The Burns Medical Practice

Yorkshire, United Kingdom

Location

Related Publications (1)

  • Stender S, Budinski D, Gosho M, Hounslow N. Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia. Eur J Prev Cardiol. 2013 Feb;20(1):40-53. doi: 10.1177/2047487312451251. Epub 2012 Jun 7.

MeSH Terms

Conditions

HypercholesterolemiaDyslipidemias

Interventions

pitavastatinPravastatin

Condition Hierarchy (Ancestors)

HyperlipidemiasLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

NaphthalenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsPolycyclic Compounds

Results Point of Contact

Title
Bill Arana
Organization
Kowa Research Institute

Study Officials

  • Dragos Budinski, MD

    Medical Director

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
GT60
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

November 21, 2005

First Posted

November 23, 2005

Study Start

September 1, 2005

Primary Completion

May 1, 2006

Study Completion

May 1, 2006

Last Updated

March 16, 2010

Results First Posted

January 18, 2010

Record last verified: 2010-03

Locations